Bumetanide analogs, compositions, and methods of use

Abstract

The present invention provides bumetanide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide analogs and methods for their use. These analogs are believed useful for the treatment and/or prophylaxis of conditions that involve the Na + K + Cl − co-transporter or GABA A receptor.

1 .- 191 . (canceled) 
     
     
         192 . A method of treating Alzheimer's Disease, Anxiety, Ascites, Autism, Bipolar Disorder, Cognition/Learning/Memory, Depression, Epilepsy, Glaucoma, Huntington's Disease, Insomnia, Ischemia, Migraine, Nociceptive Pain, Neuropathic Pain, Neurotoxicity, Postherpetic Neuralgia, Ocular Diseases, Parkinson's Disease, Schizophrenia, Tinnitus, Withdrawal Syndrome in a subject in need thereof comprising administering an effective amount of N,N-diethyl-3-aminosulfonyl-5-butylamino-4-phenoxybenzamide (bumetanide diethylamide). 
     
     
         193 . A method of reducing seizure activity in subject in need thereof comprising administering an effective amount of N,N-diethyl-3-aminosulfonyl-5-butylamino-4-phenoxybenzamide (bumetanide diethylamide). 
     
     
         194 . A method of treating idiopathic epilepsy, treating symptomatic epilepsy, treating cryptogenic epilepsy, treating status epilepticus, treating seizure disorders, reducing the rate of seizure occurrence, or reducing the severity of seizures in subject in need thereof comprising administering an effective amount of N,N-diethyl-3-aminosulfonyl-5-butylamino-4-phenoxybenzamide (bumetanidediethylamide). 
     
     
         195 . A method of treating Alzheimer's Disease, Anxiety, Ascites, Autism, Bipolar Disorder, Cognition/Learning/Memory, Depression, Epilepsy, Glaucoma, Huntington's Disease, Insomnia, Ischemia, Migraine, Nociceptive Pain, Neuropathic Pain, Neurotoxicity, Postherpetic Neuralgia, Ocular Diseases, Parkinson's Disease, Schizophrenia, Tinnitus, Withdrawal Syndrome in a subject in need thereof comprising administering an effective amount of N,N-dibenzyl-3-aminosulfonyl-5-butylamino-4-phenoxybenzamide (bumetanide dibenzylamide). 
     
     
         196 . A method of reducing seizure activity in an animal comprising administering an effective amount of N,N-dibenzyl-3-aminosulfonyl-5-butylamino-4-phenoxybenzamide (bumetanide dibenzylamide). 
     
     
         197 . A method of treating idiopathic epilepsy, treating symptomatic epilepsy, treating cryptogenic epilepsy, treating status epilepticus, treating seizure disorders, reducing the rate of seizure occurrence, or reducing the severity of seizures in subject in need thereof comprising administering an effective amount of N,N-dibenzyl-3-aminosulfonyl-5-butylamino-4-phenoxybenzamide (bumetanide dibenzylamide).